CEMIP and demyelinating disease: Here, we have found that each of the three compounds we tested increased OPC differentiation at a greater rate than S3 at similar as well as lower concentrations, suggesting that these agents have the potential to be developed for therapeutics that target CEMIP activity in demyelinating diseases.